Related Experiment Video
Updated: Aug 13, 2026

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Novel therapeutic strategies targeting growth factor signalling cascades in multiple myeloma
Hiroshi Yasui1, Teru Hideshima, Paul G Richardson
1Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA.
Abstract:
Multiple myeloma (MM) remains largely incurable despite conventional and high-dose therapies, and novel biologically based treatment approaches are urgently required. Recent studies demonstrate that various growth factors including interleukin (IL)-6, insulin-like growth factor (IGF)-1, vascular endothelial growth factor (VEGF), the tumour necrosis factor (TNF) family proteins, Wnt, and Notch family members play an important role in MM pathogenesis, and mediate tumour cell proliferation, drug resistance and migration in the bone marrow (BM) milieu. Targeting growth factors, therefore, represents a promising therapeutic strategy in MM. Novel agents inhibiting growth factor signalling cascades can target ligands, receptors, and/or downstream signalling cascade proteins in MM cells and the BM microenvironment. Combinations of these novel agents with conventional therapies may not only enhance cytotoxicity, but also avoid drug resistance and thereby improve patient outcome in MM.
Insights
Multiple myeloma (MM) is a challenging cancer. Targeting growth factors involved in MM pathogenesis offers a promising new therapeutic strategy to improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Multiple myeloma (MM) is a hematologic malignancy with limited curative options using conventional therapies.
- Growth factors like IL-6, IGF-1, VEGF, TNF, Wnt, and Notch are implicated in MM cell proliferation, drug resistance, and migration within the bone marrow microenvironment.
Purpose of the Study:
- To explore the therapeutic potential of targeting growth factor signaling pathways in multiple myeloma.
- To investigate novel biologically based treatment approaches for MM.
Main Methods:
- Review of recent studies on the role of growth factors in MM pathogenesis.
- Analysis of therapeutic strategies targeting growth factor signaling cascades (ligands, receptors, downstream proteins).
Main Results:
- Growth factors play a critical role in multiple myeloma progression and drug resistance.
- Targeting these growth factors presents a promising therapeutic avenue for MM.
Conclusions:
- Inhibiting growth factor signaling pathways offers a novel strategy for MM treatment.
- Combination therapies involving novel agents and conventional treatments may enhance efficacy and overcome drug resistance, improving patient outcomes.
More Related Videos
05:32Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice
Published on: January 7, 2019
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Abnormal Proliferation
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Differentiation of Common Myeloid Progenitor Cells